In our coverage of the inaugural meeting of the MEP Action Group for the Medical Use of Psychedelics, we discussed the challenging experience faced by a psilocybin trial participant after the support provided by the study’s protocol came to an end. On the very same day that the participant’s testimony was delivered in Brussels, Eddie Jacobs et al. published an article in Neuroethics titled…
